Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Should You Buy Omnicell (OMCL) After Golden Cross?

2026-05-22
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?

2026-05-20
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

How Much Upside is Left in Omnicell (OMCL)? Wall Street Analysts Think 39.87%

2026-05-20
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript

2026-05-19
Omnicell, Inc. (OMCL) Shareholder/Analyst Call May 19, 2026 4:30 PM EDTCompany ParticipantsRandall Lipps - Founder, Executive Chairman, President &...

3 Reasons to Avoid OMCL and 1 Stock to Buy Instead

2026-05-17
Omnicell’s 23% return over the past six months has outpaced the S&P 500 by 13%, and its stock price has climbed to $43.73 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)

2026-05-14
Omnicell, Inc. (NASDAQ:OMCL) is one of the best small cap stocks to buy for 10x potential. Omnicell, Inc. (NASDAQ:OMCL) received several rating updates following the release of its financial results for fiscal Q1 2026 on April 28. Craig-Hallum lifted the price target on the stock to $55 from $53 on April 29, reiterating a Buy […]

Omnicell's (NASDAQ:OMCL) Soft Earnings Are Actually Better Than They Appear

2026-05-14
Omnicell, Inc.'s ( NASDAQ:OMCL ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...

3 Stocks Under $50 with Warning Signs

2026-05-14
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

What Can You Expect From Omnicell Inc (OMCL) Stock After Solid Q1?

2026-05-12
Omnicell Inc (NASDAQ:OMCL) is one of the best small cap robotics stocks to buy according to analysts. Omnicell stock has gained more than 20% in the past month and climbed around 70% over the past year to trade at around $44. On April 29, KeyBanc lifted its price target on Omnicell shares to $70 from […]

Transcript : Omnicell, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08

2026-05-12
Presenter SpeechAllen Lutz To have Omnicell here. We have CFO, Baird Radford. And before I get started with questions, he has a couple of prepared remarks. Baird?AnswerH. Radford Good morning,...